Table 2 Types of infections, pathogens and dosage of 67 patients with high-dose daptomycin therapy
Characteristica | Total (n = 67) | Daptomycin dose (mg/kg) | ||
|---|---|---|---|---|
≤ 8 (n = 41) | > 8 (n = 26) | P value | ||
Pathogen | ||||
MSSA | 6 (9.0%) | 4 (9.8%) | 2 (7.7%) | 0.77 |
MRSA | 38 (56.7%) | 23 (56.1%) | 15 (57.7%) | 0.90 |
Vancomycin MIC ≥ 2 μg/mL | 24 (35.8%) | 14 (34.1%) | 10 (38.5%) | 0.80 |
MRCoNS | 10 (14.9%) | 6 (14.6%) | 4 (15.4%) | 0.93 |
VRE | 18 (26.9%) | 12 (29.3%) | 6 (23.1%) | 0.58 |
Type of infection | ||||
Community-onset | 18 (26.9%) | 10 (24.4%) | 8 (30.8%) | 0.57 |
All bacteremia | 54 (80.6%) | 32 (78.0%) | 22 (84.6%) | 0.75 |
Primary bacteremia | 10 (14.9%) | 7 (17.1%) | 3 (11.5%) | 0.54 |
Endocarditis | 11 (16.4%) | 3 (7.3%) | 8 (30.8%) | 0.03 |
Catheter-related bacteremia | 16 (23.9%) | 11 (26.8%) | 5 (19.2%) | 0.48 |
cSSTI | 16 (23.9%) | 9 (22%) | 7 (26.9%) | 0.64 |
Bone & joint infection | 9 (13.4%) | 6 (14.6%) | 3 (11.5%) | 0.72 |
Otherb | 5 (7.46%) | 5 (12.2%) | 0 (0%) | 0.15 |
Duration of therapy, days | 14 (3–53) | 13 (3–53) | 14.5 (3–42) | 0.47 |
Mean doses (mg/kg) | 7.90 | 6.98 | 9.36 | |